Trials / Completed
CompletedNCT00654498
Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)
A Randomized, Double-blind, Placebo Controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally q.n. to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 306 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To determine efficacy and safety of Pramipexole 0.125mg to 0.75mg daily for 6 weeks compared to placebo in the treatment of idiopathic Restless Legs Syndrome (RLS)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pramipexole | |
| DRUG | Placebo |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2008-04-08
- Last updated
- 2014-06-09
- Results posted
- 2010-03-03
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00654498. Inclusion in this directory is not an endorsement.